P-229: Real-world Outcomes of Sequencing Elotuzumab (Elo)-Based Regimens Following Daratumumab (dara) in Patients with Relapsed/refractory Multiple Myeloma: Results from the Connect® MM Registry
Clinical Lymphoma, Myeloma & Leukemia（2022）
关键词
International Myeloma Working Group
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要